27 January 2021
Eli Lilly announced that its neutralising antibodies bamlanivimab and etesevimab together helped in reducing the risk of Covid-19 hospitalisations and deaths, which are referred to as events, by 70% in its Phase III BLAZE-1 trial. Among 1,035 patients, there were 11 events in patients taking therapy and 36 of these events in patients taking placebo. The trial also had only 10 deaths in total, all of which occurred in the placebo group.
Care Access Research, a decentralised research organisation, and AstraZeneca have announced a collaboration to fast-track a Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination, in the US to prevent Covid-19 . The STORM CHASER trial assesses the safety and efficacy of AZD7442 for post-exposure prophylaxis and preventive treatment among 1,125 participants in the US and UK.
Shionogi and BioAge announced a license agreement that gives the latter exclusive rights to develop and market BGE-175, a prostaglandin D2 DP1 receptor antagonist, to control the severity of Covid-19 in the US and Europe. BGE-175 was discovered by Shionogi and was previously in its development stage for treating allergic rhinitis.
Foreign Minister Mohammad Javad Zarif announced that Iran has approved Russia’s Sputnik V coronavirus vaccine. Iran stated that it will only depend on vaccines developed by Russia, China, or India, while also working towards producing its own shot.